Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTK | P29376 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MST1R | Q04912 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213865 | 0.67 | DYRK1B (0.39) | LTKALKDYRK1BRETMET | |
| SCHEMBL21434271 | 0.65 | GSK3A (0.36) | ALDH1A1KDM4ENPC1RAB9AGSK3A | |
| SCHEMBL5666343 | 0.65 | PARP1 (0.44) | LTKALKDYRK1BRETMET | |
| SCHEMBL7700737 | 0.64 | PDE3B (0.39) | DYRK1BCDK8DYRK1ACHEK1PRKACA | |
| SCHEMBL11032723 | 0.64 | LTK (0.41) | LTKALKDYRK1BRETMET | |
| SCHEMBL12308496 | 0.64 | XDH (0.33) | — | |
| SCHEMBL1014318 | 0.64 | ADORA3 (0.44) | ALDH1A1KDM4EHSD17B10HPGDGLA | |
| SCHEMBL8576911 | 0.64 | HSD17B10 (0.53) | ALDH1A1KDM4EHSD17B10HPGDGLA | |
| SCHEMBL25408012 | 0.63 | MAPK8 (0.33) | DYRK1BDYRK1ACLK4ALDH1A1HSD17B10 | |
| SCHEMBL1855620 | 0.63 | LTK (0.60) | LTKALKDYRK1BRETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| CN-119894897-A | Heteroaromatic compounds for the treatment of neurological disorders | 苏文生命科学有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024042480-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693536-A | Pyrrolotriazinone compound, pharmaceutical composition containing pyrrolotriazinone compound, preparation method and application of pyrrolotriazinone compound | 上海科技大学 | 2023-09-05 | — | — | CN | disclosed |
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | UNIVERSITE DE NANTES (FR) | 2020-04-21 | — | — | US | disclosed |
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | UNIVERSITE DE NANTES (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2019-01-03 | — | — | US | disclosed |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2019-01-03 | — | — | US | disclosed |
| WO-2017020944-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021178-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS. | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2002081473-A1 | SUBSTITUTED AZOLOAZIN(THI)ONES | BAYER CROPSCIENCE AG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | LTK 3698/4885ALK 2332/4885DYRK1B 4350/4885 |
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | DHFR, SAMHD1, TYMP | LTK 2040/4885ALK 1716/4885DYRK1B 2031/4885 |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | GPR139, GPR132, GPR142 | LTK 1530/4885ALK 1893/4885DYRK1B 3108/4885 |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | SAMHD1, DHFR, TYMP | LTK 2180/4885ALK 2133/4885DYRK1B 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.